Publications
NXP100
NXP200
NXP900
- NXP900 demonstrates potent synergy with ALK inhibitors in ALK resistant cell lines (ENA 2024)
- Targeting MDSCs with NXP900 to restore antitumor immunity in NSCLC (AACR 2026)
- NXP900 in combination with RAS inhibition in NSCLC cells (AACR 2026)
- First in human phase 1 trial of NXP900 in patients with advanced solid tumors (AACR 2025)
- NXP900 blocks YAP1 signaling in NSCLC cell lines (AACR 2025)
- NXP900 as single agent and in combination with ALK inhibitors in ALK resistant NSCLC models (AACR 2025)
- Overcoming osimertinib resistance in NSCLC with NXP900 (AACR 2025)
- NXP900 inhibits tumor growth in FAT1 mutated xenograft models (ENA 2025)
- NXP900 clinical safety, PKPD and CYP450 interactions (ENA 2025)
- A Fast Method to Monitor Tyrosine Kinase Inhibitor Mechanisms (Journal of Med. Chem. 2024)
- NXP900 demonstrates potent inhibition of proliferation in cell lines resistant to ALK and EGFR inhibitors (AACR 2024)
- A multi-omics approach to identify biomarkers of response to NXP900 (ENA 2024)
- Macrophages promote anti-androgen resistance in prostate cancer bone disease (Journal of Exp. Med. 2023)
- Differences in target inhibition and anticancer efficacy between NXP900 and dasatinib (AACR 2023)
- NXP900 inhibits YAP1 nuclear localization and tumor growth in esophageal squamous cancers (ENA 2023)
- Uncovering the molecular mechanisms which predict sensitivity to NXP900 (AACR 2022)
- Screening of NXP900 and dasatinib identifies differences in their antiproliferative activity (ENA 2022)
- A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability (Cancer Res. 2021)
- Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors (Cancer Res. 2021)